A World-First in Neonatal Care: Japan Approves Prolacta Bioscience's 100% Human Milk-Based Fortifiers as a Prescription Drug for Vulnerable Infants

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Prolacta-PreemieFort

More Like This

Clinigen Announces World-First Pharmaceutical Approval for Prolacta Bioscience's PreemieFort® Enteral Solution, Human Milk-Based Product in Japan

Bifidobacterium infantis M-63 is a unique probiotic strain of human-residential bifidobacteria (HRB) – bifidobacteria that naturally reside in the human gut – and is renowned for its ability to utilize human milk oligosaccharides (HMO) found in breast milk, significantly improving the intestinal environment of healthy full-term infants. (Graphic: Business Wire)

Morinaga Milk Obtains the Registration of "New Food Ingredient" in China for use of its Probiotic Bifidobacterium infantis M-63 in Infant Foods

PR Newswire associated0

dsm-firmenich achieves regulatory clearance in China for two HMO ingredients for early life nutrition

Human-Residential Bifidobacteria (HRB) strains such as Bifidobacterium longum BB536, B. breve M-16V, B. breve MCC1274, and B. infantis M-63, significantly reduced the concentration of indole produced by Escherichia coli, a known indole producer (Figure 1). Subsequently, the research demonstrated that HRB strains can convert the potentially harmful indole into tryptophan (Trp) and beneficial indole-3-lactate (ILA) (Figure 2). The study also identified a new microbial metabolic pathway involving tryptophan synthase β subunit (TrpB) and aromatic lactate dehydrogenase (ALDH) in the conversion process (Figure 3), highlighting the sophisticated mechanisms by which specific HRB strains contribute to gut health. (Graphic: Business Wire)

Morinaga Milk’s New Research Breakthrough Backed the Superiority of its Human-Residential Bifidobacteria (HRB) Strains in Metabolizing Toxin Precursor in the Gut

PR Newswire associated0

Wyeth launches China's first infant formula with two types of HMOs, leading the way in HMO innovation

Mead Johnson Welcomes Defense Verdict in Whitfield Case

PR Newswire associated0

Yili Launches Pro-Kido Infant Formula in Hong Kong Amid Global Expansion Efforts

PR Newswire associated0

Glac Biotech Secures U.S. Food and Drug Administration GRAS Approval for Probiotic Strain CP-9